<DOC>
	<DOCNO>NCT02826837</DOCNO>
	<brief_summary>A Phase I/IIa Dose-Escalation Study Evaluating Safety , Tolerability Efficacy LEAC-102 Combination FOLFOX + Bevacizumab/Cetuximab Subjects Advanced Colorectal Cancer</brief_summary>
	<brief_title>LEAC-102 Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Subjects age least 20 year old 2 . Histologically cytologically confirm measurable and/or evaluable advanced ( stage III/IV ) colorectal cancer accurately assess CT/MRI scan ( RECIST v1.1 ) regimen FOLFOX + Bevacizumab/Cetuximab arrange investigator 3 . Subjects may treatment naïve , may receive therapy colorectal cancer . 4 . ECOG performance status ≤ 2 life expectancy ≥ 12 month Note : ECOG = Eastern Cooperative Oncology Group 5 . Dated sign informed consent 1 . Primary CNS malignancy clinically active CNS metastasis Note : CNS = central nervous system 2 . Ascertained hypersensitivity component investigational product FOLFOX + Bevacizumab/Cetuximab subject treat 3 . Any following hematologic abnormality : 1 . Hemoglobin &lt; 10.0 g/dL , 2 . ANC &lt; 1,500/μL , 3 . Platelets &lt; 100,000 /μL Note : ANC = absolute neutrophil count 4 . Any following serum chemistry abnormality : 1 . Total bilirubin &gt; 1.5 × ULN , 2 . AST ALT &gt; 2.5 × ULN , 3 . GammaGT &gt; 2.5 x ULN , 4 . AlkP &gt; 2.5 x ULN , 5. serum albumin &lt; 3.0 g/dL , 6. creatinine &gt; 1.5 × ULN , 7. ≥ Grade 3 laboratory abnormality baseline ( list ) Note : ULN = upper limit normal . AST = aspartate transaminase , ALT : alanine transaminase , GammaGT = Gammaglutamyl transferase , AlkP = alkaline phosphatase 5 . Requirement ongoing systemic steroid , immunosuppressive agent 6 . Uncontrolled nausea vomit symptom would prevent ability comply daily oral LEAC102 treatment 7 . Active clinically serious infection 8 . Known history HIV hepatitis B C Note : HIV = human immunodeficiency virus 9 . Uncontrolled psychiatric disorder alter mental status precluding inform consent necessary test 10 . Consumption herbal preparations/supplements ( except daily multivitamin/mineral supplement contain herbal component ) within 2 week prior start Cycle 1 FOLFOX + Bevacizumab/Cetuximab administration 11 . Significant cardiovascular disease , include : 1 . Active clinically symptomatic leave ventricular failure 2 . Active hypertension ( diastolic blood pressure &gt; 100 mmHg ) . Subjects history hypertension must stable dos antihypertensive drug ≥ 4 week prior start Cycle 1 FOLFOX + Bevacizumab/Cetuximab administration 3 . Uncontrolled hypertension : Blood pressure &gt; 140/90 mmHg 2 antihypertensive medication 4 . Myocardial infarction , severe angina , unstable angina within 12 week prior start Cycle 1 FOLFOX + Bevacizumab/Cetuximab administration 5 . History serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ) 12 . Significant gastrointestinal disorder ( ) would , opinion Principal Investigator , prevent absorption orally available agent 13 . Has receive investigational agent within 4 week enter study 14 . With condition judge investigator enter trial may detrimental subject 15 Female childbearing potential lactating positive urine pregnancy test Screening visit 16 . Subject either gender refuse adopt least two form birth control ( least one must barrier method ) study 30 day study treatment . Note : Acceptable form include : 1 . Established use oral , injected implant hormonal method contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . 3 . Barrier method contraception : Condom OR Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository 17 . Subjects grade 2 chronic neuropathy 18 . Subjects know dihydropyrimidine dehydrogenase ( DPD ) deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Advanced Colorectal Cancer</keyword>
</DOC>